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Cystic fibrosis (CF) is the most common lethal genetic disease in Caucasians caused by the trafficking defects of CF transmembrane
conductance regulator (CFTR), which is a cAMP-dependent Cl− channel at the plasma membrane. The trafficking pathway of CFTR is thought to
be non-conventional because CFTR maturation is inhibited by the dysfunction of syntaxin 13, which is involved in protein recycling via
endosomal pathway. In this study, to clarify whether the endosomal trafficking is required for CFTR maturation, we utilized a specific vacuolar
H+-ATPase inhibitor, bafilomycin A1 (BafA1), which inhibits the protein trafficking from early endosome. Our data showed that low
concentration of BafA1 (50nM) decreased the expression of mature CFTR but induced the accumulation of immature CFTR in the juxta-nuclear
region containing an early endosome marker. Pulse-chase analysis showed that BafA1 inhibited the maturation of CFTR, but it slightly stabilized
immature CFTR. These results indicate that BafA1-sensitive pathway is required for CFTR maturation and emphasize that endosomal trafficking
pathway might be involved in the maturation of CFTR.
© 2006 Elsevier B.V. All rights reserved.Keywords: CFTR; Bafilomycin A1; Endosome; Maturation and trafficking1. Introduction
Cystic fibrosis (CF), the most common lethal genetic disease
in Caucasians, is caused by the mutation of the gene encoding
cystic fibrosis transmembrane conductance regulator (CFTR),
which is a cAMP-dependent Cl− channel at the apical plasma
membrane of epithelial cells [1–3]. The most common mutantAbbreviations: CF, cystic fibrosis; CFTR, CF transmembrane conductance
regulator; ER, endoplasmic reticulum; BafA1, bafilomycin A1; BFA, brefeldin
A; BHK, baby hamster kidney; CHO, Chinese hamster ovary; GFP, green
fluorescence protein; ERGIC, ER-Golgi intermediate compartment
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doi:10.1016/j.bbamcr.2006.08.032of CFTR in CF patients (∼90%) is ΔF508 CFTR that has a
trafficking defect from the endoplasmic reticulum (ER) [4,5].
Since ΔF508 CFTR functions as a regulated Cl− channel [6,7],
it is very important to overcome the trafficking defect from the
ER for CF treatment. However, the trafficking pathway of
CFTR remains unclear although it is thought to be non-
conventional [8–10]. A previous report showed that CFTR
maturation is inhibited by the dysfunction of syntaxin 13 [9],
which is a soluble NEM-sensitive factor-attachment receptor
(SNARE) protein involved in protein recycling via endosomal
pathway [11], indicating that endosomal trafficking may be
involved in the maturation of CFTR.
To clarify the role of endosomal trafficking on the CFTR
maturation, we examined here the effect of bafilomycin A1
(BafA1) on the maturation of CFTR. BafA1, a group of
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inhibits vacuolar H+-ATPase [12]. BafA1 neutralizes acidic
organelles such as endosomes and inhibits the endocytotic
pathway from early endosome [13]. At high concentration,
BafA1 (1μM) inhibits the retrograde transport from Golgi to
the ER [14]. Our data showed that BafA1 at low
concentration (50nM) inhibited CFTR maturation, thereby
decreasing mature CFTR expression. BafA1 (50nM) induced
the accumulation of CFTR in the juxta-nuclear region where
Golgi and early endosome markers were localized. Inhibition
of the retrograde transport from the Golgi to the ER by high
concentration of BafA1 (1μM) resulted in the accumulation
of CFTR in the cis-Golgi, but it did not affect the maturation
of CFTR. These results indicate that BafA1-sensitive
pathway is involved in CFTR maturation and emphasizes
that endosomal trafficking might be required for the
maturation of CFTR.
2. Materials and methods
2.1. Materials and antibodies
Bafilomycin A1 (BafA1) and brefeldin A (BFA) were purchased from
Sigma-Aldrich. Anti-CFTR antibody (clone 24-1) was purchased from
Genzyme (Cambridge, MA), anti-calnexin (CNX; SPA-860), anti-Hsc70
(SPA-815), anti-KDEL (BiP; SPA-827) and anti-KDEL receptor (anti-KDELr;
clone KR-10) antibodies were from Stressgen Biotechnologies (Victoria, BC,
Canada), anti-GM130 (clone 35) and anti-p230 trans Golgi (clone 15) antibodies
were from BD Biosciences (Franklin Lakes, NJ), anti-EEA1 antibody (clone 14)
was from Transduction Laboratories (Lexington, KY), anti-ubiquitinylated
proteins antibody (clone FK-2) was from Affiniti Research Products Ltd.
(Mamhead, Exeter, UK) and anti-Myc antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA).
2.2. Cell culture and transfection
The culture and maintenance of Chinese hamster ovary (CHO) cells stably
expressing wild type CFTR (CFTR-CHO), orΔF508 CFTR (ΔF508-CHO), and
baby hamster kidney (BHK) cells overexpressing wild type CFTR (CFTR-
BHK) or ΔF508 CFTR (ΔF508-BHK) have been described [10,15,16]. Human
embryonic kidney (HEK293) cells were maintained in Dulbecco's modified
Eagle medium containing 10% fetal bovine serum and antibiotics. Transfection
was performed using calcium phosphate method. To increase CFTR expression,
cells were incubated with 1mM (for CFTR-BHK and ΔF508-BHK cells) or
2mM sodium butyrate (for CFTR-CHO and ΔF508-CHO cells) for 20–24h
before analysis.
2.3. Western blotting
Western blotting experiments were performed as described previously [16].
For N-glycanases digestion, cell lysates were denatured at 37 °C for 10min and
digested with Endo H (500U, New England Biolab, Beverly, MA) or PNGase
F (500U, New England BioLab) at 37 °C for 3h.
2.4. Pulse-chase analysis and immunoprecipitation
Pulse-chase analysis and immunoprecipitation were carried out as described
previously [16].
2.5. Immunocytochemical analysis
Immunocytochemical analyses were performed as described previously
[10,16].3. Results
3.1. Bafilomycin A1 (50nM) affects the CFTR biogenesis
To examine the effect of bafilomycin A1 (BafA1) on the
CFTR biogenesis, CHO cells stably expressing CFTR (CFTR-
CHO cells) were treated with several concentrations of BafA1
for 24h and CFTR expression was determined. Western blotting
showed that BafA1 treatment (50–200nM) increased the steady
state levels of immature CFTR (band B, Fig. 1A). Interestingly,
BafA1 (50–200nM) decreased mature CFTR (band C) and
induced the appearance of smear band of CFTR (Fig. 1A). The
effect of BafA1 was time-dependent (Fig. 1B). Six hours after
treatment (50nM and 200nM BafA1), we observed that the
expression of mature CFTR was slightly increased but not that
of immature CFTR. However, after 24h, the expression of
immature CFTR was strongly increased and the smear band of
CFTR was observed. The effect of BafA1 (50–200nM) on the
CFTR expression was similar to that of brefeldin A (BFA),
which inhibits the ER-Golgi transport [17]. BFA treatment for
24h decreased the mature CFTR expression and dramatically
increased immature CFTR (Fig. 1C). BafA1 (50nM) slightly
increased the expression of ER-localizing ΔF508 CFTR (Fig.
1D), but this increase was not as significant compared to that
with the wild type CFTR. This result indicates that the smear
bands of wild type CFTR induced by BafA1 may be derived
from the CFTR located in the post-ER compartments. Previous
reports showed that BafA1 treatment induces the mislocaliza-
tion of glycosyltransferases, leading to alterations in glycosyl-
ation [18]. Therefore, it is possible that the smear bands of
CFTR induced by BafA1 could be due to changes in
glycosylation. To clarify this possibility, we treated cell lysates
with N-glycanases prior to blotting analyses. Similar to previous
reports [19], mature CFTR was Endo H-resistant, but it was
digested by PNGase F and converted to non-glycosylated CFTR
(band A, Fig. 1E). To prove that the smear bands were not
ubiquitinylated CFTR, we performed immunoprecipitation of
the BafA1-treated CFTR-CHO cell lysates using anti-CFTR
antibody and the proteins were blotted with anti-ubiquitinylated
proteins antibody. Treatment with BafA1 for 6 or 24h did not
increase ubiquitinylated CFTR (Fig. 1F, left panel), in contrast
to the cells treated with the proteosome inhibitor, MG132 (Fig.
1F, right panel), suggesting that the smear bands observed upon
BafA1 treatment was due to changes in glycosylation, not
ubiquitination, of CFTR.
3.2. Bafilomycin A1 (50nM) inhibits the maturation of CFTR
We next determined whether BafA1 (50nM) inhibits the
maturation of CFTR. Similar to previous reports [19], our pulse-
chase analysis of CFTR-CHO cells showed that in control,
∼30% of immature CFTR was converted into mature form after
3-h chase (Fig. 2A, D). The rest of immature CFTR (∼70%)
was gradually degraded by the ERAD pathway and only ∼10%
of immature CFTR was detected after 3h (Fig. 2A, D). In the
cells treated with 50nM BafA1, efficient conversion from
immature to mature CFTR did not occur (Fig. 2B). Interestingly,
Fig. 1. Bafilomycin A1 (50nM) affects the biogenesis of CFTR. (A–D) CFTR-CHO (A, B, C) or ΔF508-CHO (D) cells were treated with bafilomycin A1 (BafA1)
(A, B, D) or brefeldin A (BFA) (C) with the concentration indicated in the figure for 24h (A) or for the time periods indicated in the figure (B–D). After treatment,
cells were lysed and analyzed by Western blotting using clone 24-1 anti-CFTR antibody. (E) BafA1 induces abnormal N-glycosylation of CFTR. Cell lysates from
CFTR-CHO cells untreated or treated with 50nM BafA1 for 24h were digested with Endo H (500U) or PNGase F (500U) for 3h and analyzed by Western
blotting. CNX and Hsc70 were used as loading control. (F) CFTR-CHO cells were untreated or treated with 50nM BafA1 for 6 or 24h or treated with 10μM
MG132 for 6h. The cell lysates were recovered and immunoprecipitated with anti-CFTR antibody and the immunoprecipitants were analyzed by Western blotting
with anti-ubiquitinylated proteins and anti-CFTR antibodies.
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immature CFTR was detected after 3 h chase (Fig. 2B, D).
However, we noted that at a high concentration (1μM), BafA1
did not significantly affect the maturation and steady state levels
of CFTR (Fig. 2C, D). These results indicate that the decrease in
the expression of mature CFTR induced by low concentration
(50nM) of BafA1 could be due to the inhibition of CFTR
maturation.
3.3. Bafilomycin A1 (50nM) affects the cellular localization of
CFTR
To examine the effect of BafA1 (50nM) on the cellular
localization of CFTR, immunocytochemical analysis was
performed using BHK cells stably expressing GFP-CFTR
(CFTR-BHK cells). In untreated cells, CFTR was mainly
localized at the plasma membrane (Fig. 3A, control). BFAtreatment, which inhibits CFTR maturation, induced the
redistribution of CFTR into the ER (Fig. 3A,+BFA). In
contrast, BafA1 (50nM) induced the accumulation of CFTR
in the juxta-nuclear region (Fig. 3A,+BafA1). To determine
the exact localization of CFTR after BafA1 treatment, cells
were immunostained with several organelle markers. Immu-
nofluorescence analysis revealed that after BafA1 treatment,
CFTR co-localized with GM130 (cis-Golgi marker), p230
(trans-Golgi marker) and EEA1 (an early endosome
marker), but not with KDEL proteins (ER) (Fig. 3B–E).
CFTR did not co-localize with ubiquitinylated proteins,
indicating that BafA1 does not induce the accumulation of
ubiquitinylated CFTR (Fig. 3F). These results were also
observed in BafA1-treated CHO cells transfected with GFP-
CFTR (data not shown). These data indicate that BafA1
induces the accumulation of CFTR in the Golgi and early
endosome.
Fig. 2. Bafilomycin A1 (50nM) inhibits the maturation of CFTR. (A–C) CFTR-CHO cells were pre-treated with 50nMBafA1 for 24h (B) and pulse-labeled with 35[S]
methionine for 20min. After the labeling, cells were incubated in the medium containing 50nM (B) or 1μM (C) BafA1 for the time periods indicated (chase).
Radiolabeled CFTRwas isolated from the cell lysates after the indicated chase periods by immunoprecipitation with anti-CFTR antibody and analyzed by SDS-PAGE.
(D) The quantification of pulse-chase experiments in panels A–C. The intensity of the band indicating immature CFTR (band B) was quantified by Image Gauge
software and expressed as a percentage of the total material present at t=0 respectively.
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the expression and cellular localization of CFTR
A previous report demonstrated that high concentration of
BafA1 (1μM) inhibits the retrograde transport from Golgi to
the ER [14] and we also showed that BafA1 treatmentFig. 3. Bafilomycin A1 (50nM) induces the accumulation of CFTR in the Golgi an
treated with 50nM BafA1 for 24h or with 5μg/ml BFA for 6h before fixation.
immunostained with anti-KDEL (B, an ER-marker), anti-GM130 (C, a cis-Golgi m
marker) or anti-ubiquitinylated proteins (F) antibodies and visualized with Alexa Flu
laser scanning microscopy. Scale bars, 10μm.induced the accumulation of CFTR in the Golgi (Fig. 3).
Thus, it is possible that the inhibition of CFTR maturation
by BafA1 is due to the inhibition of the retrograde transport
of CFTR from Golgi to the ER. To test this possibility, we
treated CFTR-BHK cells with 1μM BafA1 and observed the
cellular localization, expression and maturation of CFTR.d early endosome. (A) BHK cells stably expressing CFTR (CFTR-BHK) were
(B–F) CFTR-BHK cells treated with 50nM BafA1 for 24h were fixed and
arker), anti-p230 (D, a trans-Golgi marker), anti-EEA (E, an early endosome
or 546-conjugated secondary antibody. Analyses were performed using confocal
Fig. 4. Effect of high concentration of bafilomycin A1 (1μM) on both WT and ΔF508 CFTR. (A, B) Wild type CFTR, but not ΔF508 CFTR, is retrieved from
cis-Golgi to the ER. CFTR-BHK or ΔF508-BHK cells were treated with 1 μM BafA1 for 3h before fixation. Fixed cells were immunostained with anti-KDEL
receptor (KDELr) antibody and visualized with Alexa Fluor 546-conjugated secondary antibody. Arrowheads indicate the accumulation of KDEL receptor in the
cis-Golgi. Scale bars, 10μm. (C, D) CFTR-CHO (C) or ΔF508-CHO cells (D) were treated with 1μM BafA1 for the time periods indicated before cell lysis. Cell
lysates were analyzed by Western blotting with anti-CFTR antibody. Hsc70 was used as a loading control.
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treatment for 3h, CFTR accumulated in the juxta-nuclear
region (Fig. 4A) similar to that in 50nM BafA1 treatment.
In contrast, the cellular localization of ΔF508 CFTR, which
is constitutively localized in the ER (Fig. 4A, control), was
not affected by 1μM BafA1 treatment although KDEL
receptor, which recycles between the ER and cis-Golgi,
accumulated in the cis-Golgi (Fig. 4A, arrowheads). These
results indicate that ΔF508 CFTR was not retrieved from
cis-Golgi to the ER. Immunocytochemical analysis revealed
that CFTR was co-localized with KDEL receptor after 1μM
BafA1 treatment, suggesting that some CFTR could be
retrieved from cis-Golgi and that 1μM BafA1 inhibited this
retro-translocation (Fig. 4B). However, BafA1 did not
significantly affect the maturation and steady state level of
CFTR as clearly seen in Figs. 2C and 4C. Therefore,
retrograde transport might not be required for wild type
CFTR maturation. BafA1 (1μM) did not induce the
appearance of mature ΔF508 CFTR although it slightly
increased ΔF508 CFTR expression (Fig. 4D). These results
indicate that the inhibition of CFTR maturation by 50nM
BafA1 treatment is not due to a defect in the retrograde
transport of CFTR.4. Discussion
In this study, we utilized BafA1 to determine the role of
endosomal trafficking in CFTR maturation. Our data clearly
demonstrate that BafA1-sensitive pathway is involved in the
maturation of CFTR and emphasize that endosomal trafficking
might be required for CFTR processing. Low concentration of
BafA1 (50nM) inhibited the maturation of CFTR (Fig. 2) and
induced the appearance of smear bands of CFTR that may have
resulted from the alteration of glycosylation (Fig. 1E). By
immunoprecipitation analysis of CFTR and blotting with an
antibody for ubiquitinylated proteins, we determined that these
smear bands are not ubiquitinylated CFTR (Fig. 1F). BafA1 is
known to affect the glycosylation of proteins by relocalizing
glycosyltransferases [18]. Thus, BafA1 may inhibit CFTR
maturation by altering the glycosylation of CFTR. Interestingly,
we noted that although BafA1 (50nM) decreased the mature
CFTR form, it stabilized immature CFTR (Fig. 2B, D). It is
likely that BafA1 solely affected the CFTR trafficking to the
compartments where CFTR undergoes maturation because as
what was previously reported, stable immature CFTR (protease-
resistant form), which is conformationally matured in the ER, is
observed when the ER-Golgi transport is inhibited [19].
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induced the accumulation of CFTR in the juxta-nuclear
regions where Golgi (GM130 and p230) and early endosome
marker (EEA1) were marked (Fig. 3). Because CFTR
maturation occurs in the medial/trans-Golgi [5], BafA1
(50nM) may inhibit the CFTR trafficking from Golgi or
from early endosome to the medial/trans-Golgi compartment.
It could be argued that since BafA1 inhibits the intra-Golgi
transport by dissociating ADP-ribosylation factor (Arf1) [20]
from Golgi membrane [21], the decrease in CFTR maturation
by BafA1 could be due to a defect in the CFTR trafficking
from cis-Golgi to medial/trans-Golgi by dysregulating Arf1
function. However, CFTR maturation is Arf1-independent in
CHO cells [9], therefore, the inhibition of CFTR maturation is
most probably caused by a defect in the CFTR transport from
early endosome to medial/trans-Golgi. This interpretation is
supported by the fact that CFTR maturation is inhibited by the
disfunction of syntaxin 13 [9].
A previous report indicated that CFTR may be retrieved from
the Golgi to ER and the ER retrieval may result in inefficient
maturation of CFTR [8]. Moreover, the Golgi to ER retrieval
mechanism is thought to be involved in the ER localization of
ΔF508 CFTR [22]. Our data showed that high concentration of
BafA1 (1μM), which inhibits the retrograde transport from
cis-Golgi to the ER [14], induced the accumulation of CFTR in
the cis-Golgi (Fig. 4B), indicating that some CFTR is retrieved
from cis-Golgi to the ER. However, we noted that BafA1 (1μM)
did not significantly affect the maturation of CFTR (Fig. 4C).
Therefore, the ER retrieval mechanism may not be involved in
the inefficiency of CFTR maturation. In contrast to wt CFTR,
high concentration of BafA1 (1μM) did not affect the cellular
localization of ΔF508 CFTR (Fig. 4A), indicating that ΔF508
CFTR might not be retrieved from cis-Golgi to the ER. Thus,
we think that the ER localization of ΔF508 CFTR could result
from the defect of ER export rather than enhanced ER retrieval.
This interpretation could be supported by a previous report that
ΔF508 CFTR fails to bind to the ER export machinery [23].
Interestingly, BafA1 increased ΔF508 CFTR expression
although it did not induce maturation (Fig. 4D). Thus, some
ΔF508 CFTR may be degraded by the BafA1-sensitive
degradation pathway.
Recently (during preparation of this manuscript), Namkung
et al. reported that BafA1 treatment corrects the defect in the
maturation of ΔF508 CFTR [24]. Similar to that report, BafA1
increased the steady state level of ΔF508 CFTR (Fig. 4D).
However, we could not detect any mature bands of ΔF508
CFTR. We cannot exclude the possibility that although mature
ΔF508 CFTR might be induced by BafA1 treatment, it could
not be detected by our assay system. However, it might be
possible that BafA1 may have simply stabilized the mature form
of ΔF508 CFTR leaked from the ER since some part of ΔF508
CFTR was matured and expressed at the plasma membrane
under overexpression condition [25]. Thus, the difference
between our stable transfection system and Namkung's
transient transfection system, which induces overexpression
more than stable transfection, may have caused a difference in
the results.In conclusion, we have shown here that BafA1-sensitive
pathway is required for CFTR maturation and emphasized that
endosomal trafficking pathway might be involved in the
maturation of CFTR.
Acknowledgments
We would like to thank Dr. J. R. Riordan for providing the
CFTR-CHO, ΔF508-CHO, CFTR-BHK and ΔF508-BHK
cells. This work was supported by grants from the Ministry of
Education, Science, Sport, and Culture of Japan.
References
[1] M.P. Anderson, H.A. Berger, D.P. Rich, R.J. Gregory, A.E. Smith, M.J.
Welsh, Nucleoside triphosphates are required to open the CFTR chloride
channel, Cell 67 (1991) 775–784.
[2] J.A. Tabcharani, X.B. Chang, J.R. Riordan, J.W. Hanrahan, Phosphory-
lation-regulated Cl− channel in CHO cells stably expressing the cystic
fibrosis gene, Nature 352 (1991) 628–631.
[3] C.E. Bear, C.H. Li, N. Kartner, R.J. Bridges, T.J. Jensen, M. Ramjeesingh,
J.R. Riordan, Purification and functional reconstitution of the cystic
fibrosis transmembrane conductance regulator (CFTR), Cell 68 (1992)
809–818.
[4] J.R. Riordan, J.M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z.
Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J.L. Chou, et al., Identification
of the cystic fibrosis gene: cloning and characterization of complementary
DNA, Science 245 (1989) 1066–1073.
[5] S.H. Cheng, R.J. Gregory, J. Marshall, S. Paul, D.W. Souza, G.A. White,
C.R. O'Riordan, A.E. Smith, Defective intracellular transport and
processing of CFTR is the molecular basis of most cystic fibrosis, Cell
63 (1990) 827–834.
[6] G.M. Denning, M.P. Anderson, J.F. Amara, J. Marshall, A.E. Smith,
M.J. Welsh, Processing of mutant cystic fibrosis transmembrane
conductance regulator is temperature-sensitive, Nature 358 (1992)
761–764.
[7] S. Sato, C.L. Ward, M.E. Krouse, J.J. Wine, R.R. Kopito, Glycerol reverses
the misfolding phenotype of the most common cystic fibrosis mutation,
J. Biol. Chem. 271 (1996) 635–638.
[8] S.I. Bannykh, G.I. Bannykh, K.N. Fish, B.D. Moyer, J.R. Riordan, W.E.
Balch, Traffic pattern of cystic fibrosis transmembrane regulator through
the early exocytic pathway, Traffic 1 (2000) 852–870.
[9] J.S. Yoo, B.D. Moyer, S. Bannykh, H.M. Yoo, J.R. Riordan, W.E. Balch,
Non-conventional trafficking of the cystic fibrosis transmembrane
conductance regulator through the early secretory pathway, J. Biol.
Chem. 277 (2002) 11401–11409.
[10] T. Okiyoneda, K. Harada, K. Yamahira, I. Wada, Y. Hashimoto, K. Ueno,
M.A. Suico, T. Shuto, H. Kai, Characterization of the trafficking pathway
of cystic fibrosis transmembrane conductance regulator in baby hamster
kidney cells, J. Pharmacol. Sci. 95 (2004) 471–475.
[11] R. Prekeris, J. Klumperman, Y.A. Chen, R.H. Scheller, Syntaxin 13
mediates cycling of plasma membrane proteins via tubulovesicular
recycling endosomes, J. Cell Biol. 143 (1998) 957–971.
[12] E.J. Bowman, A. Siebers, K. Altendorf, Bafilomycins: a class of inhibitors
of membrane ATPases from microorganisms, animal cells, and plant cells,
Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 7972–7976.
[13] H. Palokangas, K. Metsikko, K. Vaananen, Active vacuolar H-ATPase is
required for both endocytic and exocytic processes during viral infection of
BHK-21 cells, J. Biol. Chem. 269 (1994) 17577–17585.
[14] H. Palokangas, M. Ying, K. Vaananen, J. Saraste, Retrograde transport
from the pre-Golgi intermediate compartment and the Golgi complex is
affected by the vacuolar H-ATPase inhibitor bafilomycin A1, Mol. Biol.
Cell 9 (1998) 3561–3578.
[15] T. Okiyoneda, I. Wada, H. Jono, T. Shuto, K. Yoshitake, N. Nakano, S.
Nagayama, K. Harada, Y. Isohama, T. Miyata, H. Kai, Calnexin Delta
185–520 partially reverses the misprocessing of the Delta F508 cystic
1023T. Okiyoneda et al. / Biochimica et Biophysica Acta 1763 (2006) 1017–1023fibrosis transmembrane conductance regulator, FEBS Lett. 526 (2002)
87–92.
[16] T. Okiyoneda, K. Harada, M. Takeya, K. Yamahira, I. Wada, T. Shuto, M.
A. Suico, Y. Hashimoto, H. Kai, Delta F508 CFTR pool in the endoplasmic
reticulum is increased by calnexin overexpression, Mol. Biol. Cell 15
(2004) 563–574.
[17] R.W. Doms, G. Russ, J.W. Yewdell, Brefeldin A redistributes resident and
itinerant Golgi proteins to the endoplasmic reticulum, J. Cell Biol. 109
(1989) 61–72.
[18] M.A. Axelsson, N.G. Karlsson, D.M. Steel, J. Ouwendijk, T. Nilsson, G.C.
Hansson, Neutralization of pH in the Golgi apparatus causes redistribution
of glycosyltransferases and changes in the O-glycosylation of mucins,
Glycobiology 11 (2001) 633–644.
[19] G.L. Lukacs, A. Mohamed, N. Kartner, X.B. Chang, J.R. Riordan, S.
Grinstein, Conformational maturation of CFTR but not its mutant
counterpart (delta F508) occurs in the endoplasmic reticulum and requires
ATP, EMBO J. 13 (1994) 6076–6086.
[20] A. Spang, ARF1 regulatory factors and COPI vesicle formation, Curr.
Opin. Cell Biol. 14 (2002) 423–427.[21] S. Zeuzem, P. Feick, P. Zimmermann, W. Haase, R.A. Kahn, I. Schulz,
Intravesicular acidification correlates with binding of ADP-ribosylation
factor to microsomal membranes, Proc. Natl. Acad. Sci. U. S. A. 89 (1992)
6619–6623.
[22] A. Gilbert, M. Jadot, E. Leontieva, S. Wattiaux-De Coninck, R. Wattiaux,
Delta F508 CFTR localizes in the endoplasmic reticulum-Golgi interme-
diate compartment in cystic fibrosis cells, Exp. Cell Res. 242 (1998)
144–152.
[23] X.Wang, J. Matteson, Y. An, B. Moyer, J.S. Yoo, S. Bannykh, I.A. Wilson,
J.R. Riordan, W.E. Balch, COPII-dependent export of cystic fibrosis
transmembrane conductance regulator from the ER uses a di-acidic exit
code, J. Cell Biol. 167 (2004) 65–74.
[24] W. Namkung, K.H. Kim, M.G. Lee, Base treatment corrects defects due to
misfolding of mutant cystic fibrosis transmembrane conductance regulator,
Gastroenterology 129 (2005) 1979–1990.
[25] S.H. Cheng, S.L. Fang, J. Zabner, J. Marshall, S. Piraino, S.C. Schiavi, D.
M. Jefferson, M.J. Welsh, A.E. Smith, Functional activation of the cystic
fibrosis trafficking mutant delta F508-CFTR by overexpression, Am. J.
Physiol. 268 (1995) L615–L624.
